TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Stock Information for TScan Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TScan Therapeutics Inc.

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA(TM) Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Heme Development Strategy
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA(TM) Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.